DrugPatentWatch Database Preview
Details for Patent: 8,013,002
Which drugs does patent 8,013,002 protect, and when does it expire?
This patent has forty-four patent family members in thirty-two countries.
Summary for Patent: 8,013,002
Title: | Methods of administering pirfenidone therapy |
Abstract: | The present invention relates to methods involving avoiding adverse drug interactions with fluvoxamine and pirfenidone or other moderate to strong inhibitors of CYP enzymes. |
Inventor(s): | Bradford; Williamson Ziegler (Ross, CA), Szwarcberg; Javier (San Francisco, CA) |
Assignee: | Intermune, Inc. (Brisbane, CA) |
Application Number: | 13/049,894 |
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 8,013,002
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Patent Submitted |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Genentech Inc | ESBRIET | pirfenidone | CAPSULE;ORAL | 022535-001 | Oct 15, 2014 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | METHOD FOR ADMINISTERING PIRFENDONE TO REDUCE DRUG INTERACTIONS WITH FLUVOXAMINE | ➤ Sign Up | ||||
Genentech Inc | ESBRIET | pirfenidone | TABLET;ORAL | 208780-001 | Jan 11, 2017 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | ADMINISTERING PIRFENIDONE CONCURRENTLY WITH FLUVOXAMINE, THE PIRFENIDONE AT A DOSE OF ABOUT 801 MG/DAY TO REDUCE DRUG INTERACTIONS WITH FLUVOXAMINE | ➤ Sign Up | ||||
Genentech Inc | ESBRIET | pirfenidone | TABLET;ORAL | 208780-001 | Jan 11, 2017 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | MODIFYING PIRFENIDONE ADMINISTRATION FROM A DOSE OF ABOUT 2400 MG/DAY DOWNWARD BY ABOUT 1600 MG/DAY WHILE CO-ADMINISTERING FLUVOXAMINE TO REDUCE DRUG INTERACTIONS WITH FLUVOXAMINE | ➤ Sign Up | ||||
Genentech Inc | ESBRIET | pirfenidone | TABLET;ORAL | 208780-003 | Jan 11, 2017 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | ADMINISTERING PIRFENIDONE CONCURRENTLY WITH FLUVOXAMINE, THE PIRFENIDONE AT A DOSE OF ABOUT 801 MG/DAY TO REDUCE DRUG INTERACTIONS WITH FLUVOXAMINE | ➤ Sign Up | ||||
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Patent Submitted |
Non-Orange Book US Patents Family Members for Patent 8,013,002
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
Patent No. | Title | Estimated Patent Expiration |
---|---|---|
8,318,780 | Methods of administering pirfenidone therapy | ➤ Sign Up |
7,816,383 | Methods of administering pirfenidone therapy | ➤ Sign Up |
7,910,610 | Methods of administering pirfenidone therapy | ➤ Sign Up |
Patent No. | Title | Estimated Patent Expiration |
International Patents Family Members for US Patent 8,013,002
Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
African Regional IP Organization (ARIPO) | 3155 | ➤ Sign Up | |||
Austria | 526024 | ➤ Sign Up | |||
Australia | 2010212490 | ➤ Sign Up | |||
Australia | 2011201462 | ➤ Sign Up | |||
Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |